News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,580 Results
Type
Article (43246)
Company Profile (464)
Press Release (685860)
Multimedia
Podcasts (109)
Webinars (20)
Section
Business (209140)
Career Advice (2032)
Deals (36087)
Drug Delivery (109)
Drug Development (83840)
Employer Resources (174)
FDA (16594)
Job Trends (15166)
News (353731)
Policy (33243)
Tag
Academia (2650)
Accelerated approval (18)
Adcomms (28)
Allergies (119)
Alliances (51113)
ALS (142)
Alzheimer's disease (1615)
Antibody-drug conjugate (ADC) (237)
Approvals (16671)
Artificial intelligence (421)
Autoimmune disease (88)
Automation (29)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (152)
Biotechnology (331)
Bladder cancer (135)
Brain cancer (48)
Breast cancer (496)
Cancer (3917)
Cardiovascular disease (326)
Career advice (1713)
Career pathing (34)
CAR-T (236)
CDC (44)
Cell therapy (638)
Cervical cancer (31)
Clinical research (70044)
Collaboration (1372)
Company closure (4)
Compensation (931)
Complete response letters (51)
COVID-19 (2739)
CRISPR (81)
C-suite (590)
Cystic fibrosis (137)
Data (4688)
Decentralized trials (2)
Denatured (35)
Depression (104)
Diabetes (426)
Diagnostics (6599)
Digital health (34)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (197)
Drug pricing (167)
Drug shortages (29)
Duchenne muscular dystrophy (204)
Earnings (90151)
Editorial (49)
Employer branding (21)
Employer resources (152)
Events (119061)
Executive appointments (956)
FDA (19062)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (16)
Funding (1243)
Gene editing (171)
Generative AI (32)
Gene therapy (523)
GLP-1 (912)
Government (4699)
Grass and pollen (5)
Guidances (363)
Healthcare (19197)
HIV (44)
Huntington's disease (38)
IgA nephropathy (63)
Immunology and inflammation (224)
Immuno-oncology (19)
Indications (58)
Infectious disease (2966)
Inflammatory bowel disease (181)
Inflation Reduction Act (16)
Influenza (95)
Intellectual property (192)
Interviews (315)
IPO (16899)
IRA (51)
Job creations (3710)
Job search strategy (1439)
Kidney cancer (15)
Labor market (73)
Layoffs (567)
Leadership (29)
Legal (8014)
Liver cancer (87)
Longevity (11)
Lung cancer (564)
Lymphoma (265)
Machine learning (30)
Management (59)
Manufacturing (606)
MASH (139)
Medical device (13774)
Medtech (13797)
Mergers & acquisitions (20074)
Metabolic disorders (1081)
Multiple sclerosis (134)
NASH (19)
Neurodegenerative disease (217)
Neuropsychiatric disorders (58)
Neuroscience (2625)
NextGen: Class of 2025 (6761)
Non-profit (4563)
Now hiring (59)
Obesity (515)
Opinion (263)
Ovarian cancer (137)
Pain (157)
Pancreatic cancer (171)
Parkinson's disease (236)
Partnered (28)
Patents (408)
Patient recruitment (321)
Peanut (53)
People (59673)
Pharmaceutical (86)
Pharmacy benefit managers (25)
Phase I (21995)
Phase II (30879)
Phase III (22860)
Pipeline (2744)
Policy (260)
Postmarket research (2603)
Preclinical (9446)
Press Release (67)
Prostate cancer (198)
Psychedelics (50)
Radiopharmaceuticals (275)
Rare diseases (650)
Real estate (6045)
Recruiting (70)
Regulatory (23997)
Reports (51)
Research institute (2449)
Resumes & cover letters (353)
Rett syndrome (15)
RNA editing (15)
RSV (67)
Schizophrenia (134)
Series A (207)
Series B (157)
Service/supplier (11)
Sickle cell disease (80)
Special edition (25)
Spinal muscular atrophy (154)
Sponsored (36)
Startups (3789)
State (2)
Stomach cancer (15)
Supply chain (94)
Tariffs (80)
The Weekly (72)
Vaccines (932)
Venture capital (65)
Weight loss (340)
Women's health (57)
Worklife (18)
Date
Today (133)
Last 7 days (666)
Last 30 days (2707)
Last 365 days (31335)
2025 (25769)
2024 (36304)
2023 (41020)
2022 (52278)
2021 (56764)
2020 (54925)
2019 (47421)
2018 (35704)
2017 (33033)
2016 (32353)
2015 (38399)
2014 (32190)
2013 (27115)
2012 (29221)
2011 (29868)
2010 (27998)
Location
Africa (746)
Alabama (77)
Alaska (7)
Arizona (278)
Arkansas (14)
Asia (40137)
Australia (6672)
California (9453)
Canada (2858)
China (887)
Colorado (396)
Connecticut (416)
Delaware (264)
Europe (87978)
Florida (1393)
Georgia (304)
Hawaii (2)
Idaho (60)
Illinois (737)
India (48)
Indiana (454)
Iowa (20)
Japan (322)
Kansas (122)
Kentucky (36)
Louisiana (19)
Maine (68)
Maryland (1235)
Massachusetts (6998)
Michigan (284)
Minnesota (546)
Mississippi (4)
Missouri (111)
Montana (31)
Nebraska (25)
Nevada (103)
New Hampshire (77)
New Jersey (2608)
New Mexico (30)
New York (2549)
North Carolina (1328)
North Dakota (9)
Northern California (4373)
Ohio (286)
Oklahoma (20)
Oregon (41)
Pennsylvania (1978)
Puerto Rico (19)
Rhode Island (44)
South America (1113)
South Carolina (48)
South Dakota (1)
Southern California (3626)
Tennessee (148)
Texas (1460)
United States (34381)
Utah (277)
Virginia (226)
Washington D.C. (78)
Washington State (800)
West Virginia (4)
Wisconsin (82)
Wyoming (1)
729,580 Results for "dmd therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Duchenne muscular dystrophy
With Prasad Back at FDA, Capricor To Fight DMD Cardiomyopathy Rejection
Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the regulator that it got it wrong. Capricor plans to resubmit the application based on deramiocel’s existing dataset.
August 20, 2025
·
7 min read
·
Heather McKenzie
Press Releases
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
August 5, 2025
·
8 min read
Press Releases
Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil
September 16, 2025
·
5 min read
Duchenne muscular dystrophy
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
September 11, 2025
·
2 min read
·
Tristan Manalac
Opinion
DMD Gene Therapy’s Inflection Point and the Case for Small Molecules
As AAV9 and CRISPR programs navigate safety, delivery and scalability hurdles, small molecules offer a deployable, scalable bridge, complementing genetic approaches and accelerating meaningful impact for patients with Duchenne muscular dystrophy.
September 4, 2025
·
6 min read
·
David Craig
Press Releases
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
October 14, 2025
·
5 min read
Gene therapy
Doctors Still Prescribing Sarepta’s DMD Gene Therapy After Safety Concerns
A new analyst survey suggests that doctors are still prescribing Sarepta’s Elevidys, even after a series of deaths in certain populations marred the gene therapy’s record.
September 16, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society
October 7, 2025
·
5 min read
Complete response letters
Capricor Plunges on FDA Rejection of DMD Cell Therapy
In its complete response letter, the FDA cited insufficient evidence establish deramiocel’s effectiveness for cardiomyopathy associated with Duchenne muscular dystrophy. The decision comes after CBER Director Vinay Prasad canceled an advisory committee meeting for the therapy.
July 11, 2025
·
3 min read
·
Tristan Manalac
Layoffs
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta Therapeutics adds a black box warning to the gene therapy for acute liver injury and failure and parts with more than a third of employees.
July 16, 2025
·
2 min read
·
Heather McKenzie
1 of 72,958
Next
